Preclinical Development of [211At]meta- Astatobenzylguanidine ([211At]MABG) As an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2022 Jul 21

PMID 35861867

Authors

Vandana Batra

Minu Samanta

Mehran Makvandi

David Groff

Paul Martorano

Jimmy Elias

Pietro Ranieri

Matthew Tsang

Catherine Hou

Yimei Li

Bruce Pawel

Daniel Martinez

Ganesan Vaidyanathan

Sean Carlin

Daniel A Pryma

John M Maris

Affiliations

Soon will be listed here.

Abstract

Purpose: [131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguanidine ([211At] MABG) is an alpha particle emitter with higher biological effectiveness and short path length which effectively sterilizes microscopic residual disease. Here we investigated the safety and antitumor activity [211At]MABG in preclinical models of neuroblastoma.

Experimental Design: We defined the maximum tolerated dose (MTD), biodistribution, and toxicity of [211At]MABG in immunodeficient mice in comparison with [131I]MIBG. We compared the antitumor efficacy of [211At]MABG with [131I]MIBG in three murine xenograft models. Finally, we explored the efficacy of [211At]MABG after tail vein xenografting designed to model disseminated neuroblastoma.

Results: The MTD of [211At]MABG was 66.7 MBq/kg (1.8 mCi/kg) in CB17SC scid-/- mice and 51.8 MBq/kg (1.4 mCi/kg) in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Biodistribution of [211At]MABG was similar to [131I]MIBG. Long-term toxicity studies on mice administered with doses up to 41.5 MBq/kg (1.12 mCi/kg) showed the radiotherapeutic to be well tolerated. Both 66.7 MBq/kg (1.8 mCi/kg) single dose and fractionated dosing 16.6 MBq/kg/fraction (0.45 mCi/kg) × 4 over 11 days induced marked tumor regression in two of the three models studied. Survival was significantly prolonged for mice treated with 12.9 MBq/kg/fraction (0.35 mCi/kg) × 4 doses over 11 days [211At]MABG in the disseminated disease (IMR-05NET/GFP/LUC) model (P = 0.003) suggesting eradication of microscopic disease.

Conclusions: [211At]MABG has significant survival advantage in disseminated models of neuroblastoma. An alpha particle emitting radiopharmaceutical may be effective against microscopic disseminated disease, warranting clinical development.

Citing Articles

Recent advances in spatio-temporally controllable systems for management of glioma.

Zhang H, Zhu W, Pan W, Wan X, Li N, Tang B Asian J Pharm Sci. 2024; 19(5):100954.

PMID: 39483717 PMC: 11525460. DOI: 10.1016/j.ajps.2024.100954.

Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.

Higuchi T, Chen X, Werner R Theranostics. 2024; 14(8):3178-3192.

PMID: 38855189 PMC: 11155404. DOI: 10.7150/thno.96743.

Recent advances in the development of Ac- and At-labeled radioligands for radiotheranostics.

Munekane M, Fuchigami T, Ogawa K Anal Sci. 2024; 40(5):803-826.

PMID: 38564087 PMC: 11035452. DOI: 10.1007/s44211-024-00514-w.

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response.

Qin S, Yang Y, Zhang J, Yin Y, Liu W, Zhang H Mol Pharm. 2023; 20(11):5543-5553.

PMID: 37788300 PMC: 10630944. DOI: 10.1021/acs.molpharmaceut.3c00427.

A At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy.

Xie L, Zhang L, Hu K, Hanyu M, Zhang Y, Fujinaga M Cell Rep Med. 2023; 4(4):100960.

PMID: 37003259 PMC: 10140459. DOI: 10.1016/j.xcrm.2023.100960.

References

Rader J, Russell M, Hart L, Nakazawa M, Belcastro L, Martinez D . Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22):6173-82. PMC: 3844928. DOI: 10.1158/1078-0432.CCR-13-1675. View

Strickland D, Vaidyanathan G, Zalutsky M . Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994; 54(20):5414-9. View

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris J . Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2011; 57(7):1124-9. DOI: 10.1002/pbc.23062. View

Vaidyanathan G, Zalutsky M . Astatine Radiopharmaceuticals: Prospects and Problems. Curr Radiopharm. 2010; 1(3):177. PMC: 2818997. DOI: 10.2174/1874471010801030177. View

Sgouros G, Bodei L, McDevitt M, Nedrow J . Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020; 19(9):589-608. PMC: 7390460. DOI: 10.1038/s41573-020-0073-9. View

Makvandi M, Xu K, Lieberman B, Anderson R, Effron S, Winters H . A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Res. 2016; 76(15):4516-24. PMC: 5549277. DOI: 10.1158/0008-5472.CAN-16-0416. View

Rokita J, Rathi K, Cardenas M, Upton K, Jayaseelan J, Cross K . Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019; 29(6):1675-1689.e9. PMC: 6880934. DOI: 10.1016/j.celrep.2019.09.071. View

Seo Y, Gustafson W, Dannoon S, Nekritz E, Lee C, Murphy S . Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012; 14(6):735-42. PMC: 3369020. DOI: 10.1007/s11307-012-0552-4. View

Dickson P, Hamner B, Ng C, Hall M, Zhou J, Hargrove P . In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg. 2007; 42(7):1172-9. DOI: 10.1016/j.jpedsurg.2007.02.027. View

10.

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

11.

Makvandi M, Dupis E, Engle J, Nortier F, Fassbender M, Simon S . Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol. 2018; 13(2):189-203. DOI: 10.1007/s11523-018-0550-9. View

12.

Mairs R, Boyd M . Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Semin Nucl Med. 2011; 41(5):334-44. DOI: 10.1053/j.semnuclmed.2011.03.004. View

13.

Vaidyanathan G, Zalutsky M . 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem. 1992; 3(6):499-503. DOI: 10.1021/bc00018a006. View

14.

Kang T, Brophy P, Hickeson M, Heyman S, Evans A, Charron M . Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol. 2003; 25(10):769-73. DOI: 10.1097/00043426-200310000-00005. View

15.

Lumbroso J, Hartmann O, Schlumberger M . Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Société Française d'Oncologie Pédiatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med (1991). 1991; 35(4):220-3. View

16.

Pouget J, Constanzo J . Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med (Lausanne). 2021; 8:692436. PMC: 8353448. DOI: 10.3389/fmed.2021.692436. View

17.

Pozzi O, Zalutsky M . Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for At labeling at high activities and radiation doses of At α-particles. Nucl Med Biol. 2016; 46:43-49. PMC: 5285439. DOI: 10.1016/j.nucmedbio.2016.11.009. View

18.

Kinuya S, Li X, Yokoyama K, Mori H, Shiba K, Watanabe N . Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma. Eur J Nucl Med Mol Imaging. 2003; 30(9):1246-50. DOI: 10.1007/s00259-003-1214-1. View

19.

McLendon R, Archer G, Garg P, Bigner D, Zalutsky M . Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys. 1996; 35(1):69-80. DOI: 10.1016/s0360-3016(96)85013-9. View

20.

Cunningham S, Mairs R, Wheldon T, Welsh P, Vaidyanathan G, Zalutsky M . Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer. 1998; 77(12):2061-8. PMC: 2150394. DOI: 10.1038/bjc.1998.348. View